



## Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st

January 30, 2022

CONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on Monday, January 31<sup>st</sup>, 2022.

The schedule for the press release and conference call/webcast is as follows:

- MAESTRO-NAFLD-1 Press Release: January 31<sup>st</sup>, 2022 at 7:00 am EST
- MAESTRO-NAFLD-1 Conference Call: January 31<sup>st</sup>, 2022 at 8:00 am EST
- Domestic Dial-In Number: (833) 660-2754
- International Dial-In Number: (409) 350-3497
- Conference ID Number: 9170277

To access the live webcast of the call please visit the Events and Presentations section of Madrigal's website or click [here](#). An archived webcast will be available on the Madrigal website after the event.

### About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of fatty liver and cardio-metabolic diseases with high unmet medical need. Madrigal's lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)- $\beta$  selective agonist that is currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in NASH (non-alcoholic steatohepatitis) patients. For more information, visit [www.madrigalpharma.com](http://www.madrigalpharma.com).

### Investor Contact

Alex Howarth, Madrigal Pharmaceuticals, Inc., [IR@madrigalpharma.com](mailto:IR@madrigalpharma.com)

### Media Contact

Christopher Frates, Madrigal Pharmaceuticals, Inc., [media@madrigalpharma.com](mailto:media@madrigalpharma.com)



Source: Madrigal Pharmaceuticals, Inc.